NO EVIDENCE OF R7128 DRUG RESISTANCE AFTER UP TO 4 WEEKS TREATMENT OF GT 1, 2 AND 3 HEPATITIS C VIRUS INFECTED INDIVIDUALS

被引：7
|
作者：
Le Pogam, S. [1 ]
Seshaadri, A. [1 ]
Kosaka, A. [1 ]
Hu, S. [1 ]
Beard, A.
Julian, S. [1 ]
Nick, C. [1 ]
Najera, I. [1 ]
机构：
[1] Roche Palo Alto LLC, Palo Alto, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2009年 / 50卷
关键词：
D O I：
10.1016/S0168-8278(09)60960-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
958
引用
收藏
页码：S348 / S348
页数：1
相关论文
共 50 条
  • [1] NO EVIDENCE OF DRUG RESISTANCE OR BASELINE S282T RESISTANCE MUTATION AMONG GT1 AND GT4 HCV INFECTED PATIENTS ON NUCLEOSIDE POLYMERASE INHIBITOR RG7128 AND PEG-IFN/RBV COMBINATION TREATMENT FOR UP TO 12 WEEKS: INTERIM ANALYSIS FROM THE PROPEL STUDY
    Le Pogam, Sophie
    Yan, Jun-Mei
    Kosaka, Alan
    Ji, Yongmei
    Gonzaludo, Nina
    Ewing, Aren
    Klumpp, Klaus
    Najera, Isabel
    HEPATOLOGY, 2010, 52 (04) : 701A - 702A
  • [2] SUPPRESSION OF IN VITRO RESISTANCE DEVELOPMENT AFTER TREATMENT OF THE HCV REPLICON WITH NS3/4A INHIBITOR ITMN-191 (R7227) IN COMBINATION WITH NUCLEOSIDE INHIBITOR R7128 OR R1626
    McCown, M.
    Rajyaguru, S.
    Kular, S.
    Cammack, N.
    Najera, I.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S349 - S349
  • [3] Predictors of sustained virological response 12 weeks after the end of treatment in hepatitis C virus GT3 infected patients receiving IFN-free antiviral treatments
    Mangia, A.
    Santoro, R.
    Cenderello, G.
    Piazzolla, V.
    Petruzzellis, D.
    Potenza, D.
    Squillante, M. M.
    Cela, M.
    De Stefano, G.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S281 - S281
  • [4] Antiretroviral Drug Resistance Surveillance among Treatment-Naive Human Immunodeficiency Virus Type 1-Infected Individuals in Angola: Evidence for Low Level of Transmitted Drug Resistance
    Bartolo, Ines
    Rocha, Cheila
    Bartolomeu, Jose
    Gama, Antonio
    Fonseca, Marlene
    Mendes, Ana
    Cristina, Filipa
    Thamm, Sven
    Epalanga, Marta
    Silva, Patricia Cavaco
    Taveira, Nuno
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (07) : 3156 - 3158
  • [5] Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C hepatitis G virus contaminated intravenous immunoglobulin: Evidence for HCV but not for GBV-C/HGV transmission
    Berger, A
    Doerr, HW
    Scharrer, I
    Weber, B
    JOURNAL OF MEDICAL VIROLOGY, 1997, 53 (01) : 25 - 30
  • [6] Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3
    Peiffer, Kai-Henrik
    Sommer, Lisa
    Susser, Simone
    Vermehren, Johannes
    Herrmann, Eva
    Doering, Matthias
    Dietz, Julia
    Perner, Dany
    Berkowski, Caterina
    Zeuzem, Stefan
    Sarrazin, Christoph
    HEPATOLOGY, 2016, 63 (01) : 63 - 73
  • [7] High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK-3682/grazoprevir/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C-CREST-1 & 2)
    Serfaty, L.
    Pianko, S.
    Ari, Z. B.
    Laursen, A. L.
    Hansen, J.
    Gane, E. J.
    Huang, H. -C.
    Jin, S.
    Bourque, J.
    Liu, H.
    Grandhi, A.
    Su, M.
    Gendrano, N.
    Fernsler, D.
    Dutko, F.
    Nguyen, B. -Y. T.
    Wahl, J.
    Barr, E.
    Yeh, W.
    Plank, R.
    Butterton, J. R.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S306 - S307
  • [8] DEVELOPMENT OF A PLATFORM TO DETECT DRUG RESISTANCE MUTATIONS IN THE NON-STRUCTURAL PROTEIN REGION OF THE HEPATITIS C VIRUS GENOTYPES 1, 2, 3, AND 4
    Dumont, S.
    Fevery, B.
    Van den Brande, K.
    Baumer, V.
    Ceulemans, H.
    De Wolf, H.
    Stuyver, L. J.
    Koletzki, D.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S124 - S124
  • [9] Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4
    McCormick, Adele L.
    Wang, Lawrence
    Garcia-Diaz, Ana
    Macartney, Malcolm J.
    Webster, Daniel P.
    Haque, Tanzina
    ANTIVIRAL THERAPY, 2015, 20 (01) : 81 - 85
  • [10] C-BREEZE 1: Efficacy and Safety of Ruzasvir 60 mg Plus Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 2, 3, 4, or 6 Infection
    Lawitz, Eric
    Poordad, Fred
    Anderson, Leah
    Vesay, Michelle
    Liu, Hong
    Fernsler, Doreen
    Asante-Appiah, Ernest
    Hanna, George J.
    Robertson, Michael
    Barr, Eliav
    Butterton, Joan R.
    Kowdley, Kris V.
    Hassanein, Tarek I.
    Sahota, Amandeep K.
    Gordon, Stuart C.
    Yeh, Wendy W.
    HEPATOLOGY, 2017, 66 : 631A - 632A
12345